Comprehensive Financial Consultants Institutional Inc. Purchases 446 Shares of Johnson & Johnson $JNJ

Comprehensive Financial Consultants Institutional Inc. grew its position in Johnson & Johnson (NYSE:JNJ) by 1.5% during the second quarter, Holdings Channel reports. The institutional investor owned 29,460 shares of the company’s stock after acquiring an additional 446 shares during the quarter. Johnson & Johnson comprises 1.5% of Comprehensive Financial Consultants Institutional Inc.’s investment portfolio, making the stock its 16th largest holding. Comprehensive Financial Consultants Institutional Inc.’s holdings in Johnson & Johnson were worth $4,500,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after purchasing an additional 6,332 shares during the last quarter. Wealth Group Ltd. purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $218,000. NewSquare Capital LLC raised its position in shares of Johnson & Johnson by 266.9% in the 1st quarter. NewSquare Capital LLC now owns 1,064 shares of the company’s stock valued at $176,000 after purchasing an additional 774 shares during the last quarter. Range Financial Group LLC raised its position in shares of Johnson & Johnson by 18.9% in the 1st quarter. Range Financial Group LLC now owns 15,886 shares of the company’s stock valued at $2,635,000 after purchasing an additional 2,529 shares during the last quarter. Finally, CHICAGO TRUST Co NA raised its position in shares of Johnson & Johnson by 0.5% in the 1st quarter. CHICAGO TRUST Co NA now owns 17,890 shares of the company’s stock valued at $2,967,000 after purchasing an additional 93 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JNJ. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a research report on Friday. Barclays raised their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Royal Bank Of Canada raised their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. Bank of America raised their price target on shares of Johnson & Johnson from $175.00 to $198.00 and gave the stock a “neutral” rating in a research report on Friday, October 3rd. Finally, Sanford C. Bernstein raised their price target on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $189.88.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $188.95 on Wednesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $455.06 billion, a price-to-earnings ratio of 20.21, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. The company has a 50 day moving average price of $177.04 and a 200-day moving average price of $163.18. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $189.92.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.